# Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

> **NCT01581398** · PHASE3 · COMPLETED · sponsor: **Xiamen Amoytop Biotech Co., Ltd.** · enrollment: 770 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Ypeginterferon alfa-2b
- **DRUG:** Pegasys
- **DRUG:** Ypeginterferon alfa-2b
- **DRUG:** Pegasys

## Key facts

- **NCT ID:** NCT01581398
- **Lead sponsor:** Xiamen Amoytop Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2014-04
- **Final completion:** 2014-06
- **Target enrollment:** 770 (ACTUAL)
- **Last updated:** 2014-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01581398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01581398, "Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01581398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*